Cimeio Therapeutics focuses on developing novel immunotherapies for hematologic disorders that deplete diseased cells while protecting healthy ones. Through epitope editing, they can edit a cell surface receptor to prevent antibody binding, while keeping the receptor functional. Their Shielded-Cell & Immunotherapy Pairs pipeline aims to improve patient outcomes from hemopoietic stem cell transplants. This novel cell therapy company, based in Switzerland and Boston, Massachusetts, was founded by Lukas Jeker, Professor at University of Basel.

Cimeio Therapeutics

Founded: 2020
Location: Basel, Switzerland
Employee range: 11 - 50
Clinical stage: RD
Therapy area: Genetic diseases
Drug types: GEN, ONC, IMM
Lead product: Undisclosed
Funding: $50M A Apr 2022

Drug notes:

About:

Jobs: